Skip to main content

Table 1 Baseline characteristics (intention to treat population)

From: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

 

SOX (n = 168)

CapeOX (n = 172)

Primary site

  

  Colon

109 (65%)

108 (63%)

  Rectum

59 (35%)

64 (37%)

Sex

  

  Male

109 (65%)

102 (59%)

  Female

59 (35%)

70 (41%)

Age

  

  ≤65 years

121 (72%)

126 (73%)

  >65 years

47 (28%)

46 (27%)

ECOG performance status

  

  0-1

164 (98%)

168 (98%)

  2

4 (2%)

4 (2%)

Previous (neo)adjuvant therapy

  

  Yes

37 (22%)

38 (22%)

  No

131 (78%)

134 (78%)

Site of metastasis

  

  Liver metastasis

105 (63%)

111 (65%)

  Non-liver metastasis

63 (37%)

61 (35%)

Number of metastatic organs

  

  One organ

65 (39%)

49 (29%)

  Two organs

61 (36%)

70 (41%)

  Three or more organs

42 (25%)

53 (31%)

Measurability

  

  Measurable lesions

155 (92%)

155 (90%)

  Assessable lesions only

13 (8%)

17 (10%)